Evaluation of a new model of care for bladder management in a statewide spinal cord service

Evaluation of a new model of care for bladder management in a statewide spinal cord service

Introduction

Bladder and bowel care is often a time-consuming long-term challenge for a person living with a spinal cord injury (SCI) regardless of injury level [1]. People living with SCI frequently require bladder management strategies because of a neurogenic bladder. However, bladder management can cause complications such as urinary tract infections (UTI), a recurrent problem for up to 60% of people living with a SCI [2, 3] and 40% of these individuals report that UTIs have a moderate to severe impact on their life [2]. Patients are at risk of developing septicaemia due to a UTI and in the first year after injury the primary cause for emergency department (ED) admissions is septicemia, disorders of the urethra and urinary tract (primarily UTIs) [4, 5]. Urinary tract infections are the second most common cause of death in people living with SCI [6]. Better bladder and bowel function rates highly amongst health priorities for people living with SCI, while urinary incontinence and urinary tract infection (UTI) are among the most distressing complaints that impact quality of life (QoL) [7, 8]. A previous population-based study of 548 incident SCI cases admitted to Victorian hospitals found that 35% of people were readmitted to hospital for a SCI related condition in the first 2 years after injury [9]. Of the people readmitted, 26% involved a urological complication. The most common readmission reason was a UTI, with the total cost of UTI readmissions and ED visits exceeding $3.3 million Australian dollars over the two year period [9].

There are many methods for managing a neurogenic bladder. Two common options are the use of an indwelling catheter (IDC) and intermittent self-catherisation (ISC). An IDC is inserted into the bladder and can remain in situ for weeks at a time. ISC involves emptying the bladder at a specified, intermittent frequency by person inserting a catheter, completely draining the bladder and then removing the catheter [10, 11]. Whilst the evidence is low, some studies have found that ISC can reduce chronic urogenital complications such as UTI [12,13,14], and the European Association of Urology (EAU) and American Urological Association (AUA) guidelines recommend the use of ISC over IDC for bladder management [11, 15]. Intermittent self-catheterisation is therefore recommended as the gold standard of care for bladder management [11, 16,17,18]. The use of IDCs previously had been standard bladder care at the Victorian Spinal Cord Service (VSCS). A retrospective review of bladder management practice at the VSCS found that ISC was associated with a lower rate of UTI in people with SCI [16]. As such, in August 2017 the VSCS introduced a new method of bladder management, ISC. Therefore, the change in practice is important to reduce the risk and rate of UTI and improve QoL for people living with SCI. The aim of this project was to evaluate the impact of a new bladder management strategy following a change from using IDC as standard care to ISC.

Methods

Setting

The VSCS is the primary care centre for people with spinal cord injuries in Victoria, Australia.

Study design and participants

A registry-based cohort study of people with SCI managed before or after the introduction of the new model of bladder management care at the VSCS was conducted. Adult (>15 years) cases of traumatic SCI with a date of injury from 1 July 2014 to 30 June 2020, and acute admission managed at the VSCS, were included. The research was conducted in compliance with the National Health and Medical Research Council of Australia’s 2023 National Statement on Ethical Conduct in Human Research. Ethics approval for this study was granted by the Austin Health Human Research Ethics Committee (Project ID 78300) and the Monash University Human Research Ethics Committee (Project ID 29749). The research was conducted with approval of a waiver of consent as existing data were used.

Procedures

Eligible cases were identified using the VSTR, the State’s population-based registry for major trauma. Data extracted from the registry included demographic information, cause (transport, fall or other) and intent of injury (intentional, unintentional, intent cannot be determined), pre-existing conditions (Charlson Comorbidity Index), nature of the SCI, the Injury Severity Score (ISS), management in the State’s trauma system (managed at the VSCS or other trauma service, inter-hospital transfer status, intensive care unit admission status), in-hospital outcomes source of funding for the admission. Data related to readmission, hospitalization and ED presentation were extracted from the Austin Health electronic medical record (EMR).

The Charlson Comorbidity Index (CCI) is used to measure mortality risk and burden of disease [19, 20]. It can be used to prognosticate patient long-term mortality [20]. The quintile of socioeconomic status was measured by applying the Index of Relative Socioeconomic Advantage and Disadvantage (IRSAD) to the patient’s postcode of residence. Range included 1 (most disadvantaged) to 5 (most advantaged) [21]. Remoteness of residence was assessed by applying the Accessibility/Remoteness Index of Australia (ARIA) which classifies the patient’s postcode of residence into 1 of 5 categories including major city, inner regional, outer regional, remove and very remote [22]. These categories were consolidated into 2 categories; major cities, and inner regional, outer regional and remote. UTI was defined using the ICD-10-AM diagnosis code, N39.0, for the admission or ED presentation.

Management strategies of bladder care included IDCs that were changed every 6 weeks. They were changed earlier if they became blocked or the patient was diagnosed with a UTI. No antibiotics were administered prior to routine changes [15, 23].

Intermittent catheterisation was completed by either the nursing staff or patient while in hospital. If completed by nursing staff a sterile technique was performed however if a patient completed the IC a clean technique was used. No catheters were re-used. Patients had the option to utilise a self-contained unit [11].

The outcomes of interest for this study included:

  1. i.

    Readmission (yes/no) and number of readmissions to hospital for UTI in the first 2 years post-injury.

  2. ii.

    ED presentation (yes/no) and number of subsequent presentations to ED for UTI in the first 2 years post-injury.

  3. iii.

    Hospitalisation (yes/no) and number of hospitalisations (ED or readmission) for UTI in the first 2 years post-injury.

The outcome of “hospitalisation” included both subsequent ED presentations and hospital readmissions at the Austin. For all analyses, ED presentations excluded the cases of hospital readmission that were via an ED; ED presentations were only where the person was managed and directly discharged from the Austin ED.

Statistical analysis

For analysis, change in the ‘pre’ model of care commenced 1 August 2017 and ended on 30 April 2017 to remove any potential confounding from early cases, where the new model of care was piloted, between 1 May and 30 July 2017. Frequencies and percentages were used to summarise categorical variables. Median values and interquartile range (IQR) or means with standard deviation (SD) were used to describe continuous data. Baseline variables were compared between model of care groups using t tests if continuous data were normally distributed, Mann–Whitney u tests for non-normally distributed continuous variables, and chi-square tests for categorical variables.

The number of readmissions to hospital, and presentations to ED, for UTI in the first 2 years post-injury were modelled using a negative binomial model to allow for the overdispersion in the data. The model was adjusted for differences in the case-mix on acute admission and an indicator variable created to account for the small proportion of cases where a full 2 years of follow-up had not yet been reached (n = 16). Adjusted incidence ratios (IRR) along with the corresponding 95% confidence intervals (CI) were reported. All analyses were performed using Stata Version 17. A p-value < 0.05 was considered significant.

Results

Three hundred and fifty-eight eligible patients with SCI were registered on the VSTR from 1 July 2014 to 30 June 2020. Fourteen people died during their acute hospital stay, and 11 people were admitted during the pilot testing phase for the new model of care. These 25 people were excluded, leaving 333 cases for analysis; 149 cases in the pre-model of care group and 184 cases in the post-model of care group (Fig. 1).

Fig. 1
Evaluation of a new model of care for bladder management in a statewide spinal cord service

Flow chart with reasons for exclusion.

Full size image

Individuals were predominantly male (77%), and the mean (SD) age was 48.3 (20.1) years. Demographic and baseline characteristics between the model of care groups are shown in Table 1. There was no association between demographic and SCI characteristics and care group except for the lower proportion of individuals receiving their definitive acute hospital care at the VSCS, and a higher ISS in the new model of care group (Table 1).

Table 1 Demographic and clinical characteristics of the cohort.
Full size table

The proportion of individuals who experienced a subsequent ED presentation for UTI was lower in the new model of care phase while the prevalence of readmission and overall hospitalisation in the first 2 years after injury was not different (Table 2).

Table 2 Subsequent ED presentations and hospital admissions for urinary tract infection.
Full size table

The rate of ED presentation was not significantly lower following the introduction of the new model of care (IRR 0.21, 95% CI: 0.08, 1.04, Fig. 2). The rate of readmission (IRR 0.21, 95% CI 0.12, 0.80), or any hospitalisation (IRR 0.3, 95% CI 0.12, 0.73), for UTI was lower following the introduction of the new bladder management model of care (Fig. 2). This reflects the lower number of repeat readmissions in the post phase (Table 2).

Fig. 2
figure 2

Association between study phase and number of subsequent hospitalisations for UTI.

Full size image

Discussion

This was the first study to compare the rate of ED presentations, admissions and hospitalisations after the transition from IDC as primary bladder management to ISC. In this study, the transition to ISC as the primary mode of bladder management was associated with lower rates of readmission and hospitalisation for UTI.

Re-hospitalisation rates for SCI have been demonstrated to be between 36–45% within the first-year post injury and approximately 30% for people with a chronic SCI (>1year) [4]. Of these 32% of presentations are associated with UTIs [4]. Our results are consistent with current literature recommending the use of ISC as gold standard bladder management [11, 16,17,18] to reduce the risk of UTIs and subsequent need for hospitalisation.

Despite the significant reduction in hospitalisations for UTI following implementation of a new model of bladder management, UTIs still occurred. Urinary tract infections remain one of the most common and distressing conditions for individuals living with a neurogenic bladder and have significant consequences for QoL and health outcomes [8, 14, 17, 24, 25]. Rates as low as 1–3 patient reported UTIs per year can significantly worsen QoL. Compared to individuals who have had no UTIs a patient’s odds of experiencing a worse quality of life increases as the rate of patient reported UTIs increases [25]. UTIs are the most common cause rehospitalisations in SCI [6]. Gabbe and Nunn (2016) found that UTI accounts for 61% of all ED costs for SCI. By reducing the number of ED presentations and subsequent hospitalisation it reduces the financial and resource burden on the healthcare system. Krause et al. [26] also found that the number of hospital bed days over the previous year was a significant predictor of increased mortality rates. Future work should focus how to reduce the number of UTIs for ISC and address potential factors impacting this rate.

A strength of this study was determining the effect implementing a new model of care had on the rate of ED presentations, admissions and hospitalisation. Previous studies have focused on the rate of UTIs in people using certain bladder management strategies [2, 17], or the rate of person reported UTIs [25], but observational studies of the impact of changing models of care are few. By understanding how a change in care impacts the hospital it helps to inform direction of care and resources. Nevertheless, there were limitations to this study. The study was observational before and after study and therefore only association and not causation could be inferred. Additionally this was a single site observational study, patients could have been admitted to hospitals other than the Austin for management of a UTI which would not have been captured in the data. Diagnosis of a UTI was made based on a patient’s presentation or admission being coded using the appropriate ICD-10-AM code. Previous data from the United States suggests this approach results in a high positive predictive value for diagnostic accuracy [27], although supporting data from Australia is not available. While ICD-10-AM coding is performed by trained coders in Australia, and there are robust audit processes for coding, our approach may have lead to over- or under-representation of the incidence of a UTI. While a randomised controlled trial (RCT) would have enabled assessment of causation, an RCT requires clinical equipoise as a foundation for justification. As there was already substantial evidence that ISC was the gold standard for clinical practice [11, 16,17,18], the justification for a clinical trial was low. ISC would not be indicated in all SCI people, though the case-mix between the phases was comparable, and a change in case-mix was unlikely to explain the findings.

The introduction of the new model of care for bladder management at the VSCS may have been associated with lower rates of ED presentation and hospitalization for UTI. A prospective study is required confirm these findings.

Related Articles

The impact of biological sex on diseases of the urinary tract

Biological sex, being female or male, broadly influences diverse immune phenotypes, including immune responses to diseases at mucosal surfaces. Sex hormones, sex chromosomes, sexual dimorphism, and gender differences all contribute to how an organism will respond to diseases of the urinary tract, such as bladder infection or cancer. Although the incidence of urinary tract infection is strongly sex biased, rates of infection change over a lifetime in women and men, suggesting that accompanying changes in the levels of sex hormones may play a role in the response to infection. Bladder cancer is also sex biased in that 75% of newly diagnosed patients are men. Bladder cancer development is shaped by contributions from both sex hormones and sex chromosomes, demonstrating that the influence of sex on disease can be complex. With a better understanding of how sex influences disease and immunity, we can envision sex-specific therapies to better treat diseases of the urinary tract and potentially diseases of other mucosal tissues.

Energy metabolism in health and diseases

Energy metabolism is indispensable for sustaining physiological functions in living organisms and assumes a pivotal role across physiological and pathological conditions. This review provides an extensive overview of advancements in energy metabolism research, elucidating critical pathways such as glycolysis, oxidative phosphorylation, fatty acid metabolism, and amino acid metabolism, along with their intricate regulatory mechanisms. The homeostatic balance of these processes is crucial; however, in pathological states such as neurodegenerative diseases, autoimmune disorders, and cancer, extensive metabolic reprogramming occurs, resulting in impaired glucose metabolism and mitochondrial dysfunction, which accelerate disease progression. Recent investigations into key regulatory pathways, including mechanistic target of rapamycin, sirtuins, and adenosine monophosphate-activated protein kinase, have considerably deepened our understanding of metabolic dysregulation and opened new avenues for therapeutic innovation. Emerging technologies, such as fluorescent probes, nano-biomaterials, and metabolomic analyses, promise substantial improvements in diagnostic precision. This review critically examines recent advancements and ongoing challenges in metabolism research, emphasizing its potential for precision diagnostics and personalized therapeutic interventions. Future studies should prioritize unraveling the regulatory mechanisms of energy metabolism and the dynamics of intercellular energy interactions. Integrating cutting-edge gene-editing technologies and multi-omics approaches, the development of multi-target pharmaceuticals in synergy with existing therapies such as immunotherapy and dietary interventions could enhance therapeutic efficacy. Personalized metabolic analysis is indispensable for crafting tailored treatment protocols, ultimately providing more accurate medical solutions for patients. This review aims to deepen the understanding and improve the application of energy metabolism to drive innovative diagnostic and therapeutic strategies.

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets

Macrophages are immune cells belonging to the mononuclear phagocyte system. They play crucial roles in immune defense, surveillance, and homeostasis. This review systematically discusses the types of hematopoietic progenitors that give rise to macrophages, including primitive hematopoietic progenitors, erythro-myeloid progenitors, and hematopoietic stem cells. These progenitors have distinct genetic backgrounds and developmental processes. Accordingly, macrophages exhibit complex and diverse functions in the body, including phagocytosis and clearance of cellular debris, antigen presentation, and immune response, regulation of inflammation and cytokine production, tissue remodeling and repair, and multi-level regulatory signaling pathways/crosstalk involved in homeostasis and physiology. Besides, tumor-associated macrophages are a key component of the TME, exhibiting both anti-tumor and pro-tumor properties. Furthermore, the functional status of macrophages is closely linked to the development of various diseases, including cancer, autoimmune disorders, cardiovascular disease, neurodegenerative diseases, metabolic conditions, and trauma. Targeting macrophages has emerged as a promising therapeutic strategy in these contexts. Clinical trials of macrophage-based targeted drugs, macrophage-based immunotherapies, and nanoparticle-based therapy were comprehensively summarized. Potential challenges and future directions in targeting macrophages have also been discussed. Overall, our review highlights the significance of this versatile immune cell in human health and disease, which is expected to inform future research and clinical practice.

Timing is everything: impact of development, ageing and circadian rhythm on macrophage functions in urinary tract infections

The bladder supports a diversity of macrophage populations with functional roles related to homeostasis and host defense, including clearance of cell debris from tissue, immune surveillance, and inflammatory responses. This review examines these roles with particular attention given to macrophage origins, differentiation, recruitment, and engagement in host defense against urinary tract infections (UTIs), where these cells recognize uropathogens through a combination of receptor-mediated responses. Time is an important variable that is often overlooked in many clinical and biological studies, including in relation to macrophages and UTIs. Given that ageing is a significant factor in urinary tract infection pathogenesis and macrophages have been shown to harbor their own circadian system, this review also explores the influence of age on macrophage functions and the role of diurnal variations in macrophage functions in host defense and inflammation during UTIs. We provide a conceptual framework for future studies that address these key knowledge gaps.

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines

The successful approval of peptide-based drugs can be attributed to a collaborative effort across multiple disciplines. The integration of novel drug design and synthesis techniques, display library technology, delivery systems, bioengineering advancements, and artificial intelligence have significantly expedited the development of groundbreaking peptide-based drugs, effectively addressing the obstacles associated with their character, such as the rapid clearance and degradation, necessitating subcutaneous injection leading to increasing patient discomfort, and ultimately advancing translational research efforts. Peptides are presently employed in the management and diagnosis of a diverse array of medical conditions, such as diabetes mellitus, weight loss, oncology, and rare diseases, and are additionally garnering interest in facilitating targeted drug delivery platforms and the advancement of peptide-based vaccines. This paper provides an overview of the present market and clinical trial progress of peptide-based therapeutics, delivery platforms, and vaccines. It examines the key areas of research in peptide-based drug development through a literature analysis and emphasizes the structural modification principles of peptide-based drugs, as well as the recent advancements in screening, design, and delivery technologies. The accelerated advancement in the development of novel peptide-based therapeutics, including peptide-drug complexes, new peptide-based vaccines, and innovative peptide-based diagnostic reagents, has the potential to promote the era of precise customization of disease therapeutic schedule.

Responses

Your email address will not be published. Required fields are marked *